These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 12915082)

  • 1. Adverse events associated with intravenous phenytoin in children: a prospective study.
    Appleton RE; Gill A
    Seizure; 2003 Sep; 12(6):369-72. PubMed ID: 12915082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Purple glove syndrome associated with intravenous phenytoin administration in a patient with severe mental and motor retardation.
    Sonohata M; Asami A; Tsunoda K; Hotokebuchi T
    J Orthop Sci; 2006 Jul; 11(4):409-11. PubMed ID: 16897209
    [No Abstract]   [Full Text] [Related]  

  • 3. Randomized evaluation of adverse events and length-of-stay with routine emergency department use of phenytoin or fosphenytoin.
    Coplin WM; Rhoney DH; Rebuck JA; Clements EA; Cochran MS; O'Neil BJ
    Neurol Res; 2002 Dec; 24(8):842-8. PubMed ID: 12500711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Purple glove syndrome caused by oral administration of phenytoin.
    Yoshikawa H; Abe T; Oda Y
    J Child Neurol; 2000 Nov; 15(11):762. PubMed ID: 11108512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pediatric use of intravenous and intramuscular phenytoin: lessons learned.
    Wheless JW
    J Child Neurol; 1998 Oct; 13 Suppl 1():S11-4; discussion S30-2. PubMed ID: 9796746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recognizing and managing purple glove syndrome.
    Snelson C; Dieckman B
    Crit Care Nurse; 2000 Jun; 20(3):54-61. PubMed ID: 11876214
    [No Abstract]   [Full Text] [Related]  

  • 7. Intravenous phenytoin and percutaneous arterial cannulation: the purple-glove syndrome.
    Mahajan RP; Batra YK; Rajeev S
    Eur J Anaesthesiol; 2007 Oct; 24(10):900-1. PubMed ID: 17977106
    [No Abstract]   [Full Text] [Related]  

  • 8. Purple glove syndrome: a complication of intravenous phenytoin.
    Hanna DR
    J Neurosci Nurs; 1992 Dec; 24(6):340-5. PubMed ID: 1289432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phenytoin administration in the newborn and infant.
    Sicca F; Contaldo A; Rey E; Dulac O
    Brain Dev; 2000 Jan; 22(1):35-40. PubMed ID: 10761832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Purple glove syndrome occurring after oral administration of phenytoin in therapeutic doses: mechanism still a dilemma.
    Jain RS; Nagpal K; Kumar S; Prakash S; Handa R
    Am J Emerg Med; 2015 Jan; 33(1):123.e5-6. PubMed ID: 25064142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence and risk factors of hypotension after intravenous fosphenytoin administration.
    Kim HK; Hwang IG; Koh IS; Kim DW
    J Clin Pharm Ther; 2017 Oct; 42(5):561-566. PubMed ID: 28439951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence and clinical consequence of the purple glove syndrome in patients receiving intravenous phenytoin.
    Coplin WM; Rhoney DH; Lyons EA; Murry KR
    Neurology; 1999 Oct; 53(7):1611-2. PubMed ID: 10534289
    [No Abstract]   [Full Text] [Related]  

  • 13. Purple glove syndrome following intravenous phenytoin administration.
    Chokshi R; Openshaw J; Mehta NN; Mohler E
    Vasc Med; 2007 Feb; 12(1):29-31. PubMed ID: 17451091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of intravenous phenytoin toxicity with demographic, clinical, and dosing parameters.
    Binder L; Trujillo J; Parker D; Cuetter A
    Am J Emerg Med; 1996 Jul; 14(4):398-401. PubMed ID: 8768165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Purple glove syndrome following intravenous phenytoin administration.
    Prince NJ; Hill C
    Arch Dis Child; 2011 Aug; 96(8):734. PubMed ID: 21628328
    [No Abstract]   [Full Text] [Related]  

  • 16. Cardiovascular adverse effects of phenytoin.
    Guldiken B; Rémi J; Noachtar S
    J Neurol; 2016 May; 263(5):861-870. PubMed ID: 26645393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The safety, tolerability, and pharmacokinetics of fosphenytoin after intramuscular and intravenous administration in neurosurgery patients.
    Boucher BA; Feler CA; Dean JC; Michie DD; Tipton BK; Smith KR; Kramer RE; Young B; Parks BR; Kugler AR
    Pharmacotherapy; 1996; 16(4):638-45. PubMed ID: 8840370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phenytoin toxicity with mandibular tremor secondary to intravenous administration.
    Türkdogan D; Onat F; Türe U; Pamir N
    Int J Clin Pharmacol Ther; 2002 Jan; 40(1):18-9. PubMed ID: 11837377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Appropriateness of intravenous loading dose of phenytoin treatment in Srinagarind Hospital.
    Tiamkao S; Chitravas N; Jitpimolmard S; Sawanyawisuth K
    J Med Assoc Thai; 2005 Nov; 88(11):1638-41. PubMed ID: 16471113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Life-threatening cardiotoxicity due to chronic oral phenytoin overdose.
    Su CM; Kung CT; Wang YC; Lu CH
    Neurol India; 2009; 57(2):200-2. PubMed ID: 19439856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.